Precision Oncology

# More choice.
More possibility.

Zentia is unlocking a new targeted approach to cancer — a biomarker-driven, oral therapy designed to give physicians and patients more options where few non-chemotherapy treatments exist today.

Discover our science → View pipeline

- Global registration-intent trials
- 300+ patients dosed
- NASDAQ: ZNTA

Oral, targeted therapy Designed for daily at-home use
Biomarker-driven Cyclin E1 positive — precision matched
Recognized for rigor at every stage

- FDA-aligned endpoints
- EMA review
- Good Clinical Practice
- ISO 27001
- Global trial network

0 Years of targeted kinase research
0 Late-stage clinical programs
0 Clinical trial sites worldwide
0 Peer-reviewed publications
Phase 3 · ASPENOVA First patient dosed Cyclin E1-positive platinum-resistant ovarian cancer

Innovating for patients

## A differentiated, targeted approach where patients need it most

Zentia is developing an oral, first-in-class therapy that targets a central regulator of cell-cycle progression — breaking down the safeguards that cancer cells rely on to survive and grow.

Built on more than a decade of WEE1 biology, our lead candidate is designed to provide physicians and patients a choice for a targeted, non-chemotherapy option where few alternatives exist today.

- Oral, at-home administration — no infusion visits
- Biomarker-defined patient selection
- Registration-intent global development program

See how we work →

Our approach

## A new kind of biomarker-directed medicine

We translate deep mechanistic science into therapies matched to the biology of each patient's disease — not just to a tumor type.

"

> Our mission is clear — to unburden patients through a more convenient, targeted approach to cancer care.

— Zentia Leadership Team
01

### Mechanism-first

We begin with the biology of cell-cycle regulation and identify the patients most likely to respond.

02

### Companion diagnostics

Biomarker-driven enrollment pairs each patient with the therapy most relevant to their tumor's biology.

03

### Patient-centered design

An oral, once-daily formulation designed to fit into daily life — not a hospital schedule.

How we work

## From discovery to patient impact

1. 01

   ### Discovery

   Deep mechanistic biology of cell-cycle control pinpoints novel, druggable targets.

2. 02

   ### Preclinical

   Compound selection, biomarker validation and registration-ready study design.

3. 03

   ### Clinical development

   Global, biomarker-driven trials advancing from first-in-human to registration.

4. 04

   ### Patient impact

   An oral, convenient therapy designed to unburden patients and their families.

Pipeline

## Clinical programs built on WEE1 biology

A focused, late-stage pipeline led by azenosertib-class therapy across biomarker-defined patient populations.

Phase 3 · ASPENOVA

### Cyclin E1-positive platinum-resistant ovarian cancer

Evaluating the first oral, non-chemotherapy, biomarker-driven approach for this patient population — transforming decades of WEE1 research into a novel targeted option.

Speak with our team

- Design Registration-intent, global
- Patient marker Cyclin E1 positive
- Dosing Oral, once daily
- Status Enrolling

Phase 2 · Registration-intent

### Uterine serous carcinoma

A differentiated, biomarker-defined target population with a significant unmet need. Our program is designed to generate registration-intent evidence in parallel with the lead indication.

Speak with our team

- Design Registration-intent, global
- Patient marker Biomarker-defined
- Dosing Oral, once daily
- Status Advancing

Preclinical · Phase 1

### Expanding the platform

Extending WEE1 biology into additional tumor types and rational combination strategies — building a durable franchise of targeted options across the oncology landscape.

Speak with our team

- Scope Multiple indications
- Combinations Rational, biomarker-led
- Dosing Oral, once daily
- Status Exploring

Get to know us

## Learn more about Zentia

### Pipeline

Our lead therapy anchors a focused, late-stage program across biomarker-defined patient populations.

View our progress →

### Investor presentation

We have built a disciplined, late-stage pipeline with a clear path to registration and commercial value.

Download presentation →

### Our leadership

Led by experience — a disciplined team with a proven track record in oncology drug development.

Meet the team →

### Contact us

Whether you're a patient, physician or investor — our team is here to help.

Get in touch →

Voices

## What our community is saying

> An oral therapy that patients can take at home is a meaningful shift. The biomarker-driven design means we can finally match the right patient to the right treatment.

DR Dr. E. Reynolds Medical Oncologist · Placeholder testimonial

> The team's depth of WEE1 biology is unmatched. It's rare to see a program so thoughtfully designed around the underlying science of the disease.

MC Dr. M. Chen Investigational Site Lead · Placeholder testimonial

> As a patient, the idea of a more convenient option — without infusion visits — gives me real hope. Zentia treats us like people, not just diagnoses.

JL J. Lopez Patient Advocate · Placeholder testimonial
Patient resources Thinking about a clinical trial? Find trial sites near you and learn what to expect at every step.

For patients & physicians

## Frequently asked questions

Answers about our investigational therapy, clinical trials, and what participation involves. Always speak with your care team about what's right for you.

###

Our lead candidate is an oral, once-daily kinase inhibitor taken at home. It targets a key regulator of cell-cycle progression that cancer cells depend on to survive and divide.

###

Trials use a companion diagnostic to identify biomarker-positive patients whose tumors carry Cyclin E1 amplification — pairing each person with the therapy most relevant to their disease biology.

###

No. It is a targeted therapy designed to interrupt a specific mechanism in cancer cells. It is being developed as a non-chemotherapy option with a more convenient, oral administration.

###

Contact our patient information team or speak with your oncologist. We can help identify a participating site and connect you with the trial team to confirm eligibility.